Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11)DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4.090(Q2/4D).

Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02855-2. PMID:35596046. IF:3.400(Q3/6D).

Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02846-3. PMID:35567734. IF:3.400(Q3/6D).

Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM clinical guideline emesis (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02802-1. PMID:35347571. IF:3.400(Q3/6D).

Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Álava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., López Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2021; 32(12)DOI:10.1016/j.annonc.2021.08.1995. PMID:34500044. IF:51.769(Q1/1D).

Valcarcel, S, Gallego, J, Jimenez-Fonseca, P, Diez, M, de Castro, EM, Hernandez, R, Arrazubi, V, Custodio, A, Cano, JM, Montes, AF, Macias, I, Visa, L, Calvo, A, Tocino, RV, Lago, NM, Limon, ML, Granja, M, Gil, M, Pimentel, P, Macia-Rivas, L, Perez, CH, Mangas, M, Carnicero, AM, Cerda, P, Gonzalez, LG, Navalon, FG, Rambla, MDM, Richard, MM, Carmona-Bayonas, A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; 149(7)DOI:10.1007/s00432-022-04294-6. PMID:36042046. IF:2.700(Q3/6D).

Isla D., Felip E., Garrido P., Insa A., Majem M., Remon J., Trigo J.M., de Castro J.. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical & Translational Oncology. 2023; 25(1)DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:2.800(Q2/5D).

Aparicio, J, Manrique, ACV, Capdevila, J, Boza, FM, Galvan, P, Richart, P, Oliveres, H, Paez, D, Hernando, J, Serrano, S, Vera, R, Hernandez-Yague, X, Gallego, RA, Riesco-Martinez, MC, de Albeniz, XG, Maurel, J. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Clinical & Translational Oncology. 2022; 24(11)DOI:10.1007/s12094-022-02868-x. PMID:35761123. IF:3.400(Q3/6D).